|
May 6
|
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
|
|
May 6
|
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
|
|
May 6
|
Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
|
|
May 2
|
Viatris to Participate in the BofA Securities 2024 Health Care Conference
|
|
May 2
|
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
|
|
May 1
|
Viatris Expands Its Wellbeing Program With the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
|
|
May 1
|
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
|
|
Apr 21
|
11 Best Low Price Pharma Stocks To Invest In
|
|
Apr 19
|
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
|
|
Apr 18
|
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
|
|
Apr 18
|
Bill Miller’s Latest 13 Stock Picks
|
|
Apr 16
|
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 15
|
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
|
|
Apr 15
|
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
|
|
Apr 4
|
Competition watchdog says HRT drug deal could raise prices
|
|
Apr 4
|
UPDATE 1-UK watchdog says Theramex-Viatris deal raises competition concerns
|
|
Apr 1
|
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
|
Apr 1
|
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
|
Apr 1
|
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
|
|
Apr 1
|
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
|